Meropenem 1000 mg

DRUG4 trials

Sponsors

Hospital Universitari de Bellvitge, N.N. Petrov National Medical Research Center of Oncology, Oslo University Hospital, Karl Landsteiner Insitute for Nephrology and Haemato-Oncology

Conditions

Anti-Bacterial AgentsAntibacterial AgentsAztreonamBladder CancerDrug EffectDrug TherapyFebrile NeutropeniaIntraperitoneal Antibiotics

Phase 2

Pharmacokinetics of Meropenem and Aztreonam After Intraperitoneal Administration Via Cycler-therapy in APD Patients Without Peritonitis

CompletedNCT07113574

Karl Landsteiner Insitute for Nephrology and Haemato-OncologyAntibacterial Agents, Anti-Bacterial Agents, Aztreonam +8

Start: 2021-08-31End: 2022-07-24Updated: 2025-08-11

Phase 3

Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery

N.N. Petrov National Medical Research Center of OncologyBladder Cancer

Start: 2022-02-02End: 2023-11-01Target: 98Updated: 2022-05-31

Phase 4

Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients

Hospital Universitari de BellvitgeFebrile Neutropenia

Start: 2019-06-05End: 2022-12-31Target: 150Updated: 2021-02-12

Unknown Phase

A Pilot Study for Optimizing Meropenem Administration in the ICU

RecruitingNCT05578586

Oslo University HospitalDrug Effect

Start: 2021-12-14End: 2027-06-30Target: 50Updated: 2025-04-24

Related Papers

Prolonged 120-h meropenem antibiotic prophylaxis in radical cystectomy compared to 24h standard antibiotic prophylaxis: Final analysis of the randomized clinical trial

Arab Journal of Urology2024-07-031 citations

Russian Randomized Trial to Select Optimal Antibiotic Prophylaxis in Radical Cystectomy: Initial Results of MACS-TRIAL (NCT05392634)

Creative Surgery and Oncology2023-03-13

Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE)

Trials2020-05-1812 citations